Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer (Q38123762)

29 August 2017

title

Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer (English)

1 reference

29 August 2017

main subject

metastatic breast cancer

1 reference

based on heuristic

inferred from title

author

Leticia De Mattos-Arruda

series ordinal

1

object named as

Leticia De Mattos-Arruda

0 references

author name string

Leticia De Mattos-Arruda

series ordinal

1

1 reference

29 August 2017

Javier Cortes

series ordinal

2

1 reference

29 August 2017

language of work or name

English

0 references

publication date

24 July 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

30

1 reference

29 August 2017

issue

7

1 reference

29 August 2017

page(s)

645-658

1 reference

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

HER2 therapy: molecular mechanisms of trastuzumab resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Adjuvant trastuzumab in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Treatment of HER2-positive breast cancer: current status and future perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Advances in first-line treatment for patients with HER-2 metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative me

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12325-013-0043-2

10.1007/S12325-013-0043-2

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1045732441

0 references

1 reference